Developer and provider of psychedelic therapies Field Trip Health Ltd. has announced the first successful dosing of a Phase 1 clinical trial on it's proprietary psychedelic molecule.
The Phase 1 trial is a double-blind, randomized, placebo-controlled study investigating the safety, tolerability, and pharmacokinetics of single, subcutaneous dose of the compound, called FT-104 HCl, in healthy volunteers.
